RAPT RAPT Therapeutics, Inc. Stock Quote

RAPT [NASD]

Index	-	P/E	-	EPS (ttm)	-2.44	Insider Own	0.30%	Shs Outstand	29.49M	Perf Week	-3.53%
Market Cap	951.70M	Forward P/E	-	EPS next Y	-3.25	Insider Trans	-81.42%	Shs Float	28.76M	Perf Month	-21.76%
Income	-64.00M	PEG	-	EPS next Q	-0.90	Inst Own	88.50%	Short Float	3.48%	Perf Quarter	-16.52%
Sales	4.40M	P/S	216.30	EPS this Y	-16.00%	Inst Trans	-1.10%	Short Ratio	3.92	Perf Half Y	62.93%
Book/sh	6.85	P/B	4.39	EPS next Y	-23.90%	ROA	-38.00%	Target Price	60.29	Perf Year	38.14%
Cash/sh	6.66	P/C	4.51	EPS next 5Y	-	ROE	-41.60%	52W Range	14.89 - 43.26	Perf YTD	52.20%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-52.00%	52W High	-30.51%	Beta	-
Dividend %	-	Quick Ratio	16.90	Sales past 5Y	-	Gross Margin	-	52W Low	101.88%	ATR	2.25
Employees	81	Current Ratio	16.90	Sales Q/Q	-33.30%	Oper. Margin	-	RSI (14)	35.60	Volatility	8.42% 6.34%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-5.70%	Profit Margin	-	Rel Volume	4.20	Prev Close	32.21
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	255.28K	Price	30.06
Recom	1.90	SMA20	-14.89%	SMA50	-10.60%	SMA200	6.24%	Volume	1,071,174	Change	-6.67%

Aug-12-21

Initiated

SVB Leerink

Outperform

$49

Jun-21-21

Initiated

Piper Sandler

Overweight

$61

Jun-01-20

Initiated

H.C. Wainwright

Buy

$40

May-19-20

Initiated

Cantor Fitzgerald

Overweight

$37

Apr-13-20

Initiated

ROTH Capital

Buy

$38

Nov-25-19

Initiated

Wells Fargo

Outperform

$33

Nov-25-19

Initiated

UBS

Buy

$26

Nov-25-19

Initiated

BMO Capital Markets

Outperform

$35

Nov-29-21 03:04PM	10 Best Growth Stocks for 2022 Insider Monkey
Nov-10-21 06:05PM	Rapt Therapeutics (RAPT) Reports Q3 Loss, Lags Revenue Estimates Zacks
04:05PM	RAPT Therapeutics Reports Third Quarter 2021 Financial Results GlobeNewswire
Nov-09-21 04:01PM	RAPT Therapeutics Appoints Industry Veteran Lori Lyons-Williams to its Board of Directors GlobeNewswire
Nov-08-21 03:00PM	Rapt Therapeutics (RAPT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release Zacks
08:00AM	RAPT Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire
Oct-29-21 09:33AM	Yale University Stock Portfolio: Top 10 Picks Insider Monkey
Oct-25-21 04:10PM	Hedge Funds Are Piling Into RAPT Therapeutics, Inc. (RAPT) Insider Monkey
Oct-18-21 08:00AM	RAPT Therapeutics Announces Upcoming Oral Presentation of RPT193 Phase 1b Data at the 4th Inflammatory Skin Disease Summit GlobeNewswire
Sep-30-21 09:15AM	RAPT Therapeutics Announces Late-Breaking Oral Presentation of Positive Results from Phase 1b Trial of RPT193 at the 30th European Academy of Dermatology and Venereology Congress GlobeNewswire
Sep-23-21 11:15AM	Companies Like RAPT Therapeutics (NASDAQ:RAPT) Are In A Position To Invest In Growth Simply Wall St.
Sep-20-21 08:00AM	RAPT Therapeutics to Present RPT193 Phase 1b Data at 30th European Academy of Dermatology and Venereology Congress GlobeNewswire -9.02%
08:00AM	RAPT Therapeutics to Present at the 2021 Cantor Virtual Healthcare Conference GlobeNewswire
Sep-10-21 04:59PM	Chief Medical Officer Of Rapt Therapeutics Makes $108.12 Thousand Sale Benzinga
Sep-03-21 08:00AM	RAPT Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Aug-11-21 08:00AM	RAPT Therapeutics Reports Second Quarter 2021 Financial Results GlobeNewswire
Aug-05-21 03:01PM	Analysts Estimate RAPT THERAPTICS (RAPT) to Report a Decline in Earnings: What to Look Out for Zacks
Jul-28-21 01:08PM	11 Best Pharma and Biotech Stocks to Buy According to Jim Simons Euclidean Capital Insider Monkey
Jul-22-21 06:11AM	RAPT Therapeutics (NASDAQ:RAPT) Shareholders Have Enjoyed A 33% Share Price Gain Simply Wall St. -5.86%
Jun-18-21 12:24PM	RAPT Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Jun-16-21 11:49AM	RAPT Reports Positive Data From Atopic Dermatitis Study Zacks -9.07%
06:55AM	RAPT Therapeutics Raises $125M Via Equity At 6% Discount Benzinga
Jun-15-21 11:07PM	RAPT Therapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire -12.07%
02:07PM	Meme Stocks Are Everywhere Theyre Just Not Always Meme Stocks Barrons.com
01:26PM	RAPT Therapeutics: Promising Clinical Data Merits a Price Target Hike TipRanks
08:40AM	RAPT Therapeutics (RAPT) is in Overbought Territory: What's Next? Zacks
Jun-14-21 04:01PM	RAPT Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire +115.51%
12:44PM	Why RAPT Therapeutics Stock Is Crushing It Today Motley Fool
08:00AM	RAPT Therapeutics Reports Positive Topline Results from Phase 1b Trial of RPT193 Monotherapy in Atopic Dermatitis GlobeNewswire
07:11AM	Crocs Is Breaking Out to a New All-Time High and It's My Stock of the Week TheStreet.com
Jun-13-21 04:00PM	RAPT Therapeutics to Report Top Line Data from Phase 1b Trial of RPT193 in Atopic Dermatitis GlobeNewswire
Jun-07-21 08:46AM	What Kind Of Shareholders Own RAPT Therapeutics, Inc. (NASDAQ:RAPT)? Simply Wall St.
May-20-21 04:00PM	RAPT Therapeutics to Present at the UBS Global Healthcare Virtual Conference GlobeNewswire
May-19-21 08:36AM	Implied Volatility Surging for RAPT Therapeutics (RAPT) Stock Options Zacks
May-11-21 08:00AM	RAPT Therapeutics Reports First Quarter 2021 Financial Results GlobeNewswire -7.08%
May-06-21 03:01PM	RAPT THERAPTICS (RAPT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release Zacks
Apr-12-21 07:49AM	Do Options Traders Know Something About RAPT Therapeutics (RAPT) Stock We Don't? Zacks
Apr-08-21 05:02AM	Who Has Been Buying RAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares? Simply Wall St.
Mar-22-21 08:00AM	RAPT Therapeutics Completes Enrollment in Phase 1b Trial of RPT193 in Atopic Dermatitis GlobeNewswire
Mar-11-21 08:00AM	RAPT Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results GlobeNewswire +13.22%
Mar-10-21 04:30PM	RAPT Therapeutics to Report Promising Preclinical Studies Supporting its Pipeline of Immunotherapy Platforms at AACR GlobeNewswire +7.05%
Mar-03-21 08:00AM	RAPT Therapeutics to Participate in Two Investor Conferences in March GlobeNewswire
Feb-22-21 09:47AM	5 Value Stocks In The Healthcare Sector Benzinga
04:11AM	RAPT Therapeutics (NASDAQ:RAPT) Is In A Strong Position To Grow Its Business Simply Wall St.
Feb-19-21 08:00AM	RAPT Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference GlobeNewswire
Jan-07-21 04:30AM	RAPT Therapeutics' (NASDAQ:RAPT) Shareholders Are Down 28% On Their Shares Simply Wall St.
Jan-05-21 08:00AM	RAPT Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-28-20 10:16AM	5 Value Stocks In The Healthcare Sector Benzinga -5.98%
Dec-15-20 11:26PM	Is RAPT A Good Stock To Buy Now? Insider Monkey
Nov-23-20 08:00AM	RAPT Therapeutics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference GlobeNewswire +7.28%
01:24AM	Rainbows and Unicorns: RAPT Therapeutics, Inc. (NASDAQ:RAPT) Analysts Just Became A Lot More Optimistic Simply Wall St.
Nov-16-20 08:00AM	RAPT Therapeutics Reports Third Quarter 2020 Financial Results GlobeNewswire -46.14%
07:30AM	RAPT Therapeutics Reports Positive Initial Data from Ongoing Phase 1/2 Clinical Trial of FLX475 in Multiple Cancer Indications GlobeNewswire
Nov-15-20 07:30AM	RAPT Therapeutics to Announce Initial Data from Phase 1/2 Clinical Trial of FLX475 in Multiple Cancer Indications GlobeNewswire
Nov-13-20 08:00AM	RAPT Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference GlobeNewswire
Nov-11-20 09:43AM	What Type Of Shareholders Make Up RAPT Therapeutics, Inc.'s (NASDAQ:RAPT) Share Registry? Simply Wall St.
Oct-14-20 08:00AM	RAPT Therapeutics Appoints Lisa Butterfield, Ph.D., and Lawrence Fong, M.D., to Scientific Advisory Board GlobeNewswire
Sep-27-20 10:25AM	The CEO, President & Director of RAPT Therapeutics, Inc. (NASDAQ:RAPT), Brian Wong, Just Bought A Few More Shares Simply Wall St.
Sep-03-20 08:32AM	RAPT Therapeutics (RAPT) Catches Eye: Stock Jumps 6.1% Zacks
08:00AM	RAPT Therapeutics to Present at Upcoming Virtual Investor Conferences GlobeNewswire
Sep-01-20 02:53PM	We're Not Worried About RAPT Therapeutics' (NASDAQ:RAPT) Cash Burn Simply Wall St. +9.66%
Aug-13-20 10:47AM	RAPT Therapeutics Reports Second Quarter 2020 Financial Results GlobeNewswire
Aug-05-20 08:00AM	RAPT Therapeutics Appoints Phyllis Loud Gray as Vice President of Human Resources GlobeNewswire
Jul-23-20 08:14PM	Wells Fargo: These 3 Strong Buy Stocks Are Must-Watch Names TipRanks
Jul-02-20 11:24AM	Insider Buying: Wendye Robbins Just Spent US$68k On RAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares Simply Wall St.
Jun-18-20 04:05PM	Peter Svennilson Elected to RAPT Therapeutics Board of Directors GlobeNewswire +11.34%
Jun-17-20 08:00AM	RAPT Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare Conference GlobeNewswire +15.62%
Jun-04-20 07:49AM	RAPT Therapeutics, Inc. (NASDAQ:RAPT) Analysts Just Trimmed Their Revenue Forecasts By 12% Simply Wall St.
May-29-20 08:00AM	RAPT Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Virtual Scientific Program GlobeNewswire
May-26-20 08:00AM	RAPT Therapeutics to Present at the Jefferies Virtual Global Healthcare Conference GlobeNewswire
May-19-20 07:47AM	Revenue Downgrade: Here's What Analysts Forecast For RAPT Therapeutics, Inc. (NASDAQ:RAPT) Simply Wall St. +6.36%
May-18-20 07:55AM	RAPT Therapeutics, Inc. (NASDAQ:RAPT) Just Reported And Analysts Have Been Cutting Their Estimates Simply Wall St.
May-17-20 10:38AM	Read This Before Selling RAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares Simply Wall St.
May-15-20 08:00AM	RAPT Therapeutics Highlights Early Results for RPT193 at Society for Investigative Dermatology Meeting GlobeNewswire +6.57%
May-14-20 08:00AM	RAPT Therapeutics Reports First Quarter 2020 Financial Results GlobeNewswire
08:00AM	RAPT Therapeutics Reports First Quarter 2020 Financial Results Globenewswire Test
May-12-20 08:00AM	RAPT Therapeutics to Present at the UBS Virtual Global Healthcare Conference GlobeNewswire
Mar-30-20 08:00AM	RAPT Therapeutics Reports Fourth Quarter 2019 Financial Results and Provides Business Update GlobeNewswire
Mar-04-20 08:00AM	RAPT Therapeutics Announces Management Promotions GlobeNewswire +18.78%
Feb-19-20 08:00AM	RAPT Therapeutics Announces Upcoming Investor Conference Presentations GlobeNewswire
Feb-07-20 06:45AM	RAPT Therapeutics Announces Pricing of $75 Million Public Offering GlobeNewswire -10.71%
Feb-04-20 05:43PM	RAPT Therapeutics Announces Proposed Offering of Common Stock GlobeNewswire
Jan-31-20 11:27AM	We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth Simply Wall St.
Jan-07-20 08:00AM	RAPT Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-16-19 08:00AM	RAPT Therapeutics to be Added to the Russell 2000® and Russell Microcap® Indices GlobeNewswire
Dec-11-19 08:00AM	RAPT Therapeutics Reports Third Quarter 2019 Financial Results and Recent Highlights GlobeNewswire -7.44%
Dec-10-19 08:00AM	RAPT Therapeutics Appoints Mary Ann Gray, Ph.D., to Board of Directors GlobeNewswire
Dec-04-19 08:00AM	RAPT Therapeutics Appoints Rodney Young as Chief Financial Officer GlobeNewswire +10.34%
07:06AM	The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug Benzinga
Dec-03-19 04:05PM	RAPT Therapeutics and Hanmi Pharmaceutical Announce Collaboration to Develop and Commercialize FLX475 in Asia GlobeNewswire +14.82%
03:29PM	Biotech IPO Frenzy Brings in 3 Stocks to Buy TipRanks
Nov-11-19 10:56AM	Weekly CEO Buys Highlight GuruFocus.com -30.25%
Oct-30-19 08:49PM	RAPT Therapeutics Announces Pricing of Initial Public Offering Business Wire
Jul-30-19 03:25PM	Rapt Therapeutics IPO: What You Need To Know Benzinga
Jul-28-19 02:08PM	IPO Outlook For The Week: Cannabis, Cancer Therapy, Sushi And Holographic AR Benzinga
Jul-05-19 05:24PM	Rapt Therapeutics files for initial public offering MarketWatch

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Robbins Wendye	Director	Oct 18	Buy	30.70	500	15,350	9,300	Oct 19 11:33 AM
Robbins Wendye	Director	Oct 13	Buy	29.69	400	11,876	8,800	Oct 15 06:25 PM
HO WILLIAM	Chief Medical Officer	Oct 13	Sale	29.69	3,000	89,070	60,106	Oct 14 01:16 PM
Brockstedt Dirk G.	Chief Scientific Officer	Oct 11	Option Exercise	6.18	2,647	16,358	22,459	Oct 12 02:48 PM
Brockstedt Dirk G.	Chief Scientific Officer	Oct 11	Sale	30.78	2,647	81,475	19,812	Oct 12 02:48 PM
COLUMN GROUP II, LP	10% Owner	Sep 27	Option Exercise	26.93	9,239	248,818	7,500	Sep 29 04:58 PM
COLUMN GROUP II, LP	10% Owner	Sep 27	Sale	34.57	9,239	319,397	0	Sep 29 04:58 PM
HO WILLIAM	Chief Medical Officer	Sep 20	Sale	40.00	2,000	80,000	63,106	Sep 22 06:27 PM
HO WILLIAM	Chief Medical Officer	Sep 17	Sale	38.97	2,000	77,930	63,106	Sep 20 01:58 PM
COLUMN GROUP II, LP	10% Owner	Sep 15	Sale	37.35	33,535	1,252,418	0	Sep 16 05:16 PM
COLUMN GROUP II, LP	10% Owner	Sep 14	Sale	36.94	147,676	5,454,800	0	Sep 16 05:16 PM
COLUMN GROUP II, LP	10% Owner	Sep 13	Sale	35.27	14,317	504,943	36,633	Sep 14 05:31 PM
Brockstedt Dirk G.	Chief Scientific Officer	Sep 10	Option Exercise	6.18	2,648	16,365	22,460	Sep 13 01:29 PM
Brockstedt Dirk G.	Chief Scientific Officer	Sep 10	Sale	35.78	2,648	94,745	19,812	Sep 13 01:29 PM
COLUMN GROUP II, LP	10% Owner	Sep 10	Sale	35.19	21,738	765,007	41,421	Sep 14 05:31 PM
HO WILLIAM	Chief Medical Officer	Sep 08	Sale	36.04	3,000	108,120	65,106	Sep 09 07:36 PM
COLUMN GROUP II, LP	10% Owner	Sep 02	Sale	35.43	37,101	1,314,552	0	Sep 03 04:09 PM
COLUMN GROUP II, LP	10% Owner	Sep 01	Sale	35.23	31,749	1,118,592	18,545	Sep 03 04:09 PM
Robbins Wendye	Director	Aug 24	Buy	30.99	525	16,270	2,000	Aug 25 09:08 PM
COLUMN GROUP II, LP	10% Owner	Aug 24	Sale	31.42	22,867	718,413	0	Aug 24 08:52 PM
Robbins Wendye	Director	Aug 23	Buy	31.39	1,475	46,295	1,475	Aug 25 09:08 PM
COLUMN GROUP II, LP	10% Owner	Aug 23	Sale	31.34	68,340	2,141,570	11,418	Aug 24 08:52 PM
Robbins Wendye	Director	Aug 20	Buy	29.53	600	17,716	8,400	Aug 23 07:04 PM
COLUMN GROUP II, LP	10% Owner	Aug 20	Sale	30.08	4,539	136,533	34,076	Aug 24 08:52 PM
HO WILLIAM	Chief Medical Officer	Aug 16	Sale	32.07	1,000	32,070	68,106	Aug 17 07:24 PM
Brockstedt Dirk G.	Chief Scientific Officer	Aug 11	Option Exercise	6.18	2,647	16,358	22,459	Aug 12 05:27 PM
Brockstedt Dirk G.	Chief Scientific Officer	Aug 11	Sale	31.19	2,647	82,560	19,812	Aug 12 05:27 PM
HO WILLIAM	Chief Medical Officer	Aug 06	Option Exercise	12.00	3,690	44,280	69,106	Aug 09 01:28 PM
HO WILLIAM	Chief Medical Officer	Aug 04	Option Exercise	6.24	694	4,331	65,416	Aug 06 01:22 PM
HO WILLIAM	Chief Medical Officer	Aug 02	Sale	30.52	1,000	30,520	64,722	Aug 03 06:05 PM
HO WILLIAM	Chief Medical Officer	Jul 23	Option Exercise	6.26	8,193	51,283	65,722	Jul 26 03:59 PM
HO WILLIAM	Chief Medical Officer	Jul 15	Sale	30.23	1,000	30,230	57,529	Jul 16 01:00 PM
Brockstedt Dirk G.	Chief Scientific Officer	Jul 12	Option Exercise	6.18	2,648	16,365	22,460	Jul 13 02:35 PM
Brockstedt Dirk G.	Chief Scientific Officer	Jul 12	Sale	33.53	2,648	88,787	19,812	Jul 13 02:35 PM
Robbins Wendye	Director	Jul 07	Buy	30.18	1,000	30,180	7,800	Jul 08 01:32 PM
HO WILLIAM	Chief Medical Officer	Jul 01	Sale	31.75	1,000	31,750	58,529	Jul 02 12:49 PM
Robbins Wendye	Director	Jun 16	Buy	31.61	5	158	305	Jun 21 05:06 PM
Robbins Wendye	Director	Jun 16	Buy	31.54	700	22,079	6,800	Jun 21 05:06 PM
HO WILLIAM	Chief Medical Officer	Jun 15	Sale	43.26	1,000	43,260	59,529	Jun 17 01:23 PM
HO WILLIAM	Chief Medical Officer	Jun 14	Sale	40.00	2,000	80,000	60,529	Jun 16 06:53 PM
Brockstedt Dirk G.	Chief Scientific Officer	Jun 11	Option Exercise	6.18	2,647	16,358	22,459	Jun 15 08:51 PM
Brockstedt Dirk G.	Chief Scientific Officer	Jun 11	Sale	18.55	2,647	49,102	19,812	Jun 15 08:51 PM
HO WILLIAM	Chief Medical Officer	Jun 01	Sale	19.50	1,000	19,500	62,529	Jun 02 05:39 PM
HO WILLIAM	Chief Medical Officer	May 17	Sale	19.87	1,000	19,870	63,529	May 19 04:36 PM
Brockstedt Dirk G.	Chief Scientific Officer	May 11	Option Exercise	6.18	2,648	16,365	22,460	May 13 07:32 PM
Brockstedt Dirk G.	Chief Scientific Officer	May 11	Sale	18.19	2,648	48,167	19,812	May 13 07:32 PM
Brockstedt Dirk G.	Chief Scientific Officer	May 05	Sale	21.56	2,084	44,931	19,812	May 06 06:20 PM
HO WILLIAM	Chief Medical Officer	May 03	Sale	22.04	1,000	22,040	64,529	May 05 02:06 PM
HO WILLIAM	Chief Medical Officer	Apr 15	Sale	21.14	1,000	21,140	63,445	Apr 16 02:11 PM
Robbins Wendye	Director	Apr 13	Buy	19.46	700	13,620	6,100	Apr 14 09:03 PM
Robbins Wendye	Director	Apr 09	Buy	21.04	800	16,831	1,300	Apr 13 07:18 PM
Robbins Wendye	Director	Apr 09	Buy	21.12	600	12,674	5,400	Apr 13 07:18 PM
HO WILLIAM	Chief Medical Officer	Mar 15	Sale	21.91	1,000	21,910	65,445	Mar 17 12:58 PM
HO WILLIAM	Chief Medical Officer	Mar 01	Sale	18.60	1,000	18,600	66,445	Mar 02 12:47 PM
Brockstedt Dirk G.	Chief Scientific Officer	Feb 16	Option Exercise	6.28	9,877	62,029	29,689	Feb 17 09:36 PM
HO WILLIAM	Chief Medical Officer	Feb 16	Sale	21.81	1,000	21,810	67,445	Feb 17 09:39 PM
Brockstedt Dirk G.	Chief Scientific Officer	Feb 16	Sale	21.22	9,877	209,590	19,812	Feb 17 09:36 PM
HO WILLIAM	Chief Medical Officer	Feb 01	Sale	19.99	1,000	19,990	66,414	Feb 02 07:27 PM
HO WILLIAM	Chief Medical Officer	Jan 15	Sale	21.05	1,000	21,050	67,414	Jan 15 08:52 PM
Brockstedt Dirk G.	Chief Scientific Officer	Jan 06	Sale	19.68	1,179	23,203	17,556	Jan 06 08:48 PM
Brockstedt Dirk G.	Chief Scientific Officer	Jan 05	Sale	19.76	821	16,225	18,735	Jan 06 08:48 PM
HO WILLIAM	Chief Medical Officer	Jan 04	Sale	19.75	1,000	19,750	68,414	Jan 04 08:04 PM
Brockstedt Dirk G.	Chief Scientific Officer	Dec 30	Option Exercise	6.18	9,300	57,474	19,556	Dec 31 06:09 PM
HO WILLIAM	Chief Medical Officer	Dec 15	Sale	24.55	1,000	24,550	69,414	Dec 15 09:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience